86.95
-3.78 (-4.17%)
| Previous Close | 90.73 |
| Open | 90.00 |
| Volume | 792,874 |
| Avg. Volume (3M) | 486,658 |
| Market Cap | 4,213,805,568 |
| Price / Sales | 14.00 |
| Price / Book | 51.93 |
| 52 Weeks Range | |
| Earnings Date | 18 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -91.87% |
| Operating Margin (TTM) | -44.13% |
| Diluted EPS (TTM) | -6.58 |
| Quarterly Revenue Growth (YOY) | 81.30% |
| Total Debt/Equity (MRQ) | 207.00% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | -132.57 M |
| Levered Free Cash Flow (TTM) | -42.44 M |
| Return on Assets (TTM) | -26.44% |
| Return on Equity (TTM) | -171.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Axsome Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 16.68% |
| % Held by Institutions | 81.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alethea Capital Management, Llc | 30 Sep 2024 | 738,503 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 180.00 (HC Wainwright & Co., 107.02%) | Buy |
| Median | 130.00 (49.51%) | |
| Low | 116.00 (Baird, 33.41%) | Buy |
| Average | 135.60 (55.95%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 95.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 12 Dec 2024 | 121.00 (39.16%) | Buy | 94.37 |
| HC Wainwright & Co. | 27 Nov 2024 | 180.00 (107.02%) | Buy | 99.65 |
| 25 Nov 2024 | 180.00 (107.02%) | Buy | 97.50 | |
| Baird | 13 Nov 2024 | 116.00 (33.41%) | Buy | 97.83 |
| Needham | 13 Nov 2024 | 130.00 (49.51%) | Buy | 97.83 |
| 12 Nov 2024 | 130.00 (49.51%) | Buy | 99.49 | |
| RBC Capital | 04 Oct 2024 | 131.00 (50.66%) | Buy | 86.59 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Nov 2024 | Announcement | Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 |
| 29 Oct 2024 | Announcement | Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 |
| 15 Oct 2024 | Announcement | Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |